Compare iShares MSCI Australia ETF (EWA) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs 22nd Century Group Inc — how do they compare? iShares MSCI Australia ETF trades at $29.88, while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). The key difference: iShares MSCI Australia ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| EWA | XXII | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $30.41 | $801.00 |
52-Week Low | $24.95 | $3.72 |
Market Cap | — | $1.52M |
Enterprise Value | — | -$6.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA trades at $29.89, down 0.53% on the day, with a bullish technical signal supported by moving averages. The stock shows neutral oscillator readings, with RSI near 69 indicating mild overbought conditions. A dividend of $0.40 is scheduled for June 2026, providing income appeal. Recent news highlights partnerships and economic developments affecting Australian markets, though specific financial ratios are unavailable.
Outlook is cautiously optimistic due to technical strength, but limited fundamental data poses valuation challenges. Risks include reliance on Australian economic conditions and market volatility. Investors should seek updated financials for a complete assessment, as current metrics are not provided, emphasizing the need for due diligence amid geopolitical and regulatory factors.
22nd Century Group (XXII) trades at $4.31, down 0.92% on the day, with a neutral technical signal and bearish moving averages. The company shows deep unprofitability with a gross margin of -52.19% and net margin of -65.76%, though revenue was $7.05M in 2025. Recent corporate actions include a 20:1 reverse stock split in June 2026, and news highlights retail expansion for VLN reduced-nicotine cigarettes in California and New York.
The outlook remains speculative with high execution risk amid persistent losses, but analyst sentiment is bullish with 75% buy ratings. Key risks include negative cash flow from operations, regulatory hurdles for tobacco products, and the need for successful commercialization of VLN to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
